Wall Street Journal opinion: “not a single published study has demonstrated that patients with a prior infection benefit from Covid-19 vaccination. That this isn’t readily acknowledged by the CDC or Anthony Fauci is an indication of how deeply entangled pandemic politics is in science.”
We’ve spent two days scouring the internet looking for Plan B for what happens in the event of complete Covid-19 vaccine failure. So what does happen if the vaccines fail? Here is what we have found so far:
Actually, we found no results. It seems that no one is even asking the question. Perhaps it’s time to start that conversation?
** UPDATE 31ST JULY 2021 ** Finally, the UK government takes a look out of the front windscreen to see what is oncoming rather looking out of the rear-view mirror to look at the pile-up that has just occurred.
Researchers reported that among 20 fully-vaccinated healthcare workers with vaccine breakthrough COVID-19 cases, all were infected with coronavirus variants. An earlier study had linked breakthrough infections with low viral loads, suggesting low transmission risks, but “we found many samples in our breakthrough cohort with high viral load,” said coauthor Pavitra Roychoudhury of the University of Washington. CONTAGIOUS: “Our work suggests that not all breakthrough infections are at low risk of initiating transmission and, if they did, these infections could lead to the continued spread of variants of concern, particularly in areas with low vaccination rates.”
The CDC has genetic data for virus samples from 555 vaccine breakthrough infections. Mutated variants of the coronavirus, including those first seen in the UK and South Africa, accounted for 64% of the breakthroughs.
Medrxix preprint – Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State
China’s first domestically developed mRNA vaccine is ready to start its final stage trials overseas next month.The vaccine – which uses the same advanced revolutionary techniques as the drugs developed by Pfizer-BioNTech and Moderna – is at the end of phase 2 human trials and will start large-scale phase 3 trials next month, Ying Bo, founder and chief executive of Suzhou Abogen Biosciences, told China National Radio.
The vaccine, known as ARCoV, has been jointly developed by Abogen, the Academy of Military Science and Walvax Biotechnology.